No Fees Unless We Win
(310) 207-3233
Menu

Dexilant Stomach Cancer Lawsuit

Dexilant is a prescription heartburn medication made by Takeda, the same company that makes Prevacid. Individuals diagnosed with stomach cancer after taking Dexilant (dexlansoprazole) or its generic for a prolonged period of time may wish to explore whether they have a potential legal claim. Wisner Baum is currently reviewing potential Dexilant stomach cancer lawsuits nationwide. Patients and families can contact the firm for a free, confidential case evaluation. 

What is Dexilant (Dexlansoprazole)?

Dexilant (dexlansoprazole) is a proton pump inhibitor (PPI) used to treat heartburn, gastroesophageal reflux disease (GERD), and erosive esophagitis. The prescription medication works by decreasing the amount of acid in a person’s stomach. Dexilant is available by prescription only. 

The drug was first approved by the FDA in January 2009 under the name Kapidex. The Food and Drug Administration subsequently approved a name change to Dexilant in 2010 as a result of confusion with two unrelated drugs at pharmacies, Kadian and Casodex. An authorized generic version entered the U.S. market in December 2021, and other generic versions have followed.

Dexilant is a delayed-release capsule that releases the drug in two stages after it is taken and is approved for people 12 and older. Unlike Prilosec, Nexium, and Prevacid, which are also sold over the counter, Dexilant is available by prescription only. 

The FDA label lists treatment periods that vary by indication, including up to eight weeks to heal erosive esophagitis, four weeks for heartburn associated with symptomatic non-erosive GERD, and up to six months to maintain healed erosive esophagitis and relieve heartburn in adults.

Dexilant's Manufacturer Takeda Also Makes Prevacid

Japanese pharmaceutical company Takeda makes both Dexilant and Prevacid. Dexilant contains dexlansoprazole, the R-enantiomer of lansoprazole, the active ingredient in Prevacid. Though related, the medications have different formulations and release characteristics. 

Dexilant launched in 2009, the same year the FDA approved the first generic versions of Prevacid. Dexilant received FDA approval in January 2009. Teva announced FDA approval of its generic Prevacid delayed-release capsules in November of that year.

Unlike Prevacid, Dexilant uses a two-stage design in which one capsule releases the drug in two waves a few hours apart. The delayed-release, two-stage design set it apart from Prevacid and other medications already on the market.

According to the Dexilant label, in a five-day study of healthy adults, Dexilant 60 mg kept stomach pH above 4 for about 17 hours a day, compared with about 14 hours for lansoprazole 30 mg, the active ingredient in Prevacid. 

Research on Dexilant and Stomach Cancer

According to the Dexilant label, the carcinogenic potential of the drug was assessed using lansoprazole studies. In two 24-month studies, rats given lansoprazole daily at doses of 5 to 150 mg/kg/day developed dose-related gastric ECL cell hyperplasia (an overgrowth of certain cells in the stomach lining) and ECL cell carcinoid tumors. The label also reports that lansoprazole increased the incidence of intestinal metaplasia of the stomach lining in both male and female rats.

Researchers have studied the efficacy, safety, and potential side effects of proton pump inhibitors for decades and generally examine them as a group of drugs. A 2019 review published in Therapeutic Advances in Gastroenterology concluded that multiple observational studies suggest an association between long-term use of PPIs and an increased risk of gastric cancer development. The risk, however, was “likely limited” to individuals with a current or past history of H. pylori infection, particularly if they had underlying precancerous gastric lesions.

A 2025 review in BMJ Open Gastroenterology found that 20 of 21 meta-analyses reported an association between long-term PPI use and gastric cancer. The authors cautioned that observational studies are vulnerable to bias and confounding, and the question remains disputed. A January 2026 BMJ study in five Nordic countries found no association between long-term PPI use and gastric non-cardia adenocarcinoma. The study excluded cancers arising in the gastric cardia, near the junction of the esophagus and stomach.

Research into the potential relationship between PPI use and stomach cancer remains ongoing. Several factors may contribute to differing findings, including study design, patient populations, and duration of use. 

What Dexilant Stomach Cancer Lawsuits Allege

Stomach cancer lawsuits filed against PPI manufacturers allege that the companies knew or should have known that long-term use of their drugs could increase a person’s risk of stomach cancer and failed to warn patients or doctors. Claims asserted in these cases have included failure to warn, design defect, negligence, and fraudulent concealment, and families have brought wrongful death claims on behalf of loved ones. Takeda has also disclosed that some plaintiffs in earlier litigation alleged that Prevacid and/or Dexilant caused gastric cancer (see below).

Dexilant’s label states that, in adults, a symptomatic response to treatment does not rule out gastric malignancy (stomach cancer), and it advises doctors to consider follow-up and diagnostic testing for adult patients who respond poorly or relapse early. Plaintiffs in PPI stomach cancer cases contend that this type of warning addresses whether a drug can mask an existing cancer, not whether long-term use may increase cancer risk.

Dexilant and the Earlier PPI Kidney Litigation

According to Takeda’s annual financial report to the US Securities and Exchange Commission (SEC), more than 6,100 product liability lawsuits related to Prevacid and Dexilant had been filed in U.S. federal and state courts as of March 31, 2024. Most of the cases were consolidated into a multi-district litigation (MDL) being heard in a federal court in New Jersey. The cases alleged that patients developed kidney injuries and, in some cases, stomach cancer, as a result of taking Prevacid and/or Dexilant and that Takeda failed to adequately warn them of the potential risks. 

Takeda reached an agreement in principle to resolve the U.S. cases in April 2024 and executed a final settlement agreement in November 2024. The terms are confidential. The stomach cancer claims Wisner Baum is now reviewing are separate, individual lawsuits. 

Who May Be Eligible to File a Dexilant Lawsuit

Individuals who took Dexilant or Kapidex long-term and were subsequently diagnosed with stomach cancer may be eligible to file a lawsuit against the drug maker. Families may also be able to file on behalf of a loved one who has died. People who took generic dexlansoprazole should also reach out; whether a claim can be brought, and against which company, depends on state law and the facts of the case.

Wisner Baum is also evaluating stomach cancer claims involving other PPIs, including Prevacid, Nexium, and Prilosec. Many people switched between PPIs over the years, and taking more than one does not by itself rule out a claim. Because Dexilant requires a prescription, pharmacy records can help document use.

Is There a Deadline to File a Dexilant Lawsuit?

The amount of time a person has to file a Dexilant lawsuit depends on a state-specific deadline known as a statute of limitations. These deadlines range from one year to several years, depending on the state. The deadline may start from the date of diagnosis or from when a person could have reasonably discovered that the cancer may have been linked to use of the drug. Wrongful death claims may be subject to a different deadline. 

Missing the statute of limitations can end a person’s right to file. An attorney can review the timeline of a claim during the free consultation and help determine whether it falls within the applicable deadline. 

Compensation That May Be Available in a Dexilant Claim

Individuals filing a Dexilant claim may seek to recover compensation for medical bills, lost income, and pain and suffering. Families of loved ones who have died may pursue compensation for funeral costs and the loss of their loved one. 

In some cases, punitive damages (extra damages meant to punish a company) may be possible to pursue. However, no result is guaranteed, and each claim’s value depends significantly on the independent facts of the case.

Why Choose Wisner Baum for Your Dexilant Stomach Cancer Claim

For the past four decades, attorneys with Wisner Baum have worked tirelessly to pursue justice for people harmed nationwide by dangerous or defective drugs and products, recovering over $4 billion in verdicts and settlements. 

One of the best-known examples is when Managing Partner R. Brent Wisner was co-lead trial counsel in Pilliod v. Monsanto, where a jury returned a $2.055 billion verdict, later reduced by the court. Wisner, along with firm partner Monique Alarcon, also filed one of the first PPI stomach cancer cases in the country.

Request a Free Dexilant Case Evaluation

Individuals who have been diagnosed with stomach cancer after long-term Dexilant use or family members of a loved one who has died may request a free, confidential case review. Contact Wisner Baum today at (310) 207-3233 to schedule a case evaluation. There are no attorney fees unless there is a recovery.

Get Started
Call (310) 207-3233 or fill out the form below and request a free consultation.
20,000+ Families Represented

"Wisner Baum gave exceptional attention to all aspects of the case, detailed inquiry, and tenacious overview of all the information submitted. The paralegals are efficient and diligent. I was completely surprised to find an empathic personal message to take care of my own health during the challenging time of being a full-time caretaker.*"

Mary Flores
Reviewed
on Google
Read More Reviews
Case Results
We Demand Accountability.
More Successful Results
$2.0 Billion Verdict
Personal Injury
In May of 2019, the jury in the case of Pilliod et al. v, Monsanto Company ordered the agrochemical giant to pay $2.055 billion in damages to the plaintiffs, Alva and Alberta Pilliod, a Bay Area couple in their 70s. R. Brent Wisner served as co-lead trial attorney for the Pilliods, delivering the opening and closing statements and cross-examining several of Monsanto’s experts. Wisner Baum managing shareholder, Michael Baum and attorney Pedram Esfandiary also served on the trial team in the Pilliod case. The judge later reduced their award to $87M. Monsanto appealed the Pilliod’s verdict which the California Court of Appeal for the First Appellate District denied on August 9, 2021. Monsanto then requested the California Supreme Court review the appeal’s court decision, which the court denied on Nov. 17, 2021. Monsanto (Bayer) then submitted a petition for a writ of certiorari with the U.S. Supreme Court which SCOTUS denied on June 27, 2022, allowing the final judgment of $87M to remain intact.
In May of 2019, the jury in the case of Pilliod et al. v, Monsanto Company ordered the agrochemical giant to pay $2.055 billion in damages to the plaintiffs, Alva and Alberta Pilliod, a Bay Area couple in their 70s. R. Brent Wisner served as co-lead trial attorney for the Pilliods, delivering the opening and closing statements and cross-examining several of Monsanto’s experts. Wisner Baum managing shareholder, Michael Baum and attorney Pedram Esfandiary also served on the trial team in the Pilliod case. The judge later reduced their award to $87M. Monsanto appealed the Pilliod’s verdict which the California Court of Appeal for the First Appellate District denied on August 9, 2021. Monsanto then requested the California Supreme Court review the appeal’s court decision, which the court denied on Nov. 17, 2021. Monsanto (Bayer) then submitted a petition for a writ of certiorari with the U.S. Supreme Court which SCOTUS denied on June 27, 2022, allowing the final judgment of $87M to remain intact.
Continue Reading
$2.0 Billion Verdict
Personal Injury

In May of 2019, the jury in the case of Pilliod et al. v, Monsanto Company ordered the agrochemical giant to pay $2.055 billion in damages to the plaintiffs, Alva and Alberta Pilliod, a Bay Area couple in their 70s. R. Brent Wisner served as co-lead trial attorney for the Pilliods, delivering the opening and closing statements and cross-examining several of Monsanto’s experts. Wisner Baum managing shareholder, Michael Baum and attorney Pedram Esfandiary also served on the trial team in the Pilliod case.

The judge later reduced their award to $87M. Monsanto appealed the Pilliod’s verdict which the California Court of Appeal for the First Appellate District denied on August 9, 2021. Monsanto then requested the California Supreme Court review the appeal’s court decision, which the court denied on Nov. 17, 2021. Monsanto (Bayer) then submitted a petition for a writ of certiorari with the U.S. Supreme Court which SCOTUS denied on June 27, 2022, allowing the final judgment of $87M to remain intact.

$289.2 Million Verdict
Personal Injury
$289.2 million jury verdict in Monsanto Roundup trial Wisner Baum co-represented Dewayne “Lee” Johnson in the first Roundup cancer lawsuit to proceed to trial. On Aug. 10, 2018, a San Francisco jury ordered Monsanto to pay $39.25 million in compensatory damages and $250 million in punitive damages to Mr. Johnson, a former groundskeeper who alleged exposure to Monsanto’s herbicides caused him to develop terminal non-Hodgkin lymphoma. Months after the jury verdict, the judge overseeing the trial reduced the punitive damages to $39.25 million. Mr. Johnson decided to accept the remittitur, bringing the adjusted amount awarded to Mr. Johnson $78.5 million. Monsanto (Bayer) appealed the verdict and Johnson cross appealed. On July 20, 2020, the First Circuit Court of Appeals upheld the verdict against Monsanto but reduced Mr. Johnson’s award to $20.5 million. The company chose not to take the case to the U.S. Supreme Court, ending the litigation.
$289.2 million jury verdict in Monsanto Roundup trial Wisner Baum co-represented Dewayne “Lee” Johnson in the first Roundup cancer lawsuit to proceed to trial. On Aug. 10, 2018, a San Francisco jury ordered Monsanto to pay $39.25 million in compensatory damages and $250 million in punitive damages to Mr. Johnson, a former groundskeeper who alleged exposure to Monsanto’s herbicides caused him to develop terminal non-Hodgkin lymphoma. Months after the jury verdict, the judge overseeing the trial reduced the punitive damages to $39.25 million. Mr. Johnson decided to accept the remittitur, bringing the adjusted amount awarded to Mr. Johnson $78.5 million. Monsanto (Bayer) appealed the verdict and Johnson cross appealed. On July 20, 2020, the First Circuit Court of Appeals upheld the verdict against Monsanto but reduced Mr. Johnson’s award to $20.5 million. The company chose not to take the case to the U.S. Supreme Court, ending the litigation.
Continue Reading
$289.2 Million Verdict
Personal Injury

$289.2 million jury verdict in Monsanto Roundup trial

Wisner Baum co-represented Dewayne “Lee” Johnson in the first Roundup cancer lawsuit to proceed to trial. On Aug. 10, 2018, a San Francisco jury ordered Monsanto to pay $39.25 million in compensatory damages and $250 million in punitive damages to Mr. Johnson, a former groundskeeper who alleged exposure to Monsanto’s herbicides caused him to develop terminal non-Hodgkin lymphoma.

Months after the jury verdict, the judge overseeing the trial reduced the punitive damages to $39.25 million. Mr. Johnson decided to accept the remittitur, bringing the adjusted amount awarded to Mr. Johnson $78.5 million.

Monsanto (Bayer) appealed the verdict and Johnson cross appealed. On July 20, 2020, the First Circuit Court of Appeals upheld the verdict against Monsanto but reduced Mr. Johnson’s award to $20.5 million. The company chose not to take the case to the U.S. Supreme Court, ending the litigation.

$265 Million Settlement
Fatal Train Crash
In 2016, Wisner Baum attorney Timothy A. Loranger and six other attorneys in the Plaintiffs’ Management Committee were able to secure a $265 million settlement for victims of the 2015 Amtrak 188 derailment in Philadelphia, one of the largest in the U.S. for 2016.
In 2016, Wisner Baum attorney Timothy A. Loranger and six other attorneys in the Plaintiffs’ Management Committee were able to secure a $265 million settlement for victims of the 2015 Amtrak 188 derailment in Philadelphia, one of the largest in the U.S. for 2016.
Continue Reading
$265 Million Settlement
Fatal Train Crash

In 2016, Wisner Baum attorney Timothy A. Loranger and six other attorneys in the Plaintiffs’ Management Committee were able to secure a $265 million settlement for victims of the 2015 Amtrak 188 derailment in Philadelphia, one of the largest in the U.S. for 2016.

Dexilant Stomach Cancer Lawsuit FAQs

Dexilant is a proton pump inhibitor that reduces stomach acid production. The active ingredient in Dexilant is dexlansoprazole. Dexilant capsules use a dual delayed-release formulation.

Takeda disclosed in 2024 that more than 6,100 product liability lawsuits related to Prevacid and Dexilant had been filed in U.S. courts. Plaintiffs in those cases alleged kidney injuries or, in some cases, gastric cancer. Takeda resolved those U.S. cases through a confidential settlement finalized in November 2024. Wisner Baum is now reviewing new, individual stomach cancer claims involving Dexilant and other PPI drugs. 

The generic name of Dexilant is dexlansoprazole. 

Individuals who took generic dexlansoprazole can contact Wisner Baum for a case specific review. Medication use and a subsequent stomach cancer diagnosis do not, by themselves, establish eligibility to file a lawsuit.

While Dexilant and Prevacid are both proton pump inhibitors made by the same company, they do differ. Dexilant is a prescription medication with the active ingredient dexlansoprazole. Prevacid contains lansoprazole and is available in prescription and over-the-counter formulations.

Dexilant and Kapidex are the same medication. The maker of the drug changed the name to avoid confusion with two other unrelated medications.

The amount of time a family or individual has to file a Dexilant lawsuit depends on a state-specific statute of limitations. During an initial case evaluation, an attorney can help to determine if the claim is within the statutory deadline.

Individuals who took a proton pump inhibitor other than Dexilant may still qualify for a claim and are encouraged to speak with an attorney.

There is no single definition. Many studies, including the 2026 Nordic study discussed above, define long-term PPI use as more than one year. 

Wisner Baum is reviewing potential individual stomach cancer claims involving Dexilant, rather than claims brought as part of a class action.

When companies choose profit over people, we fight. Wisner Baum exposes injustice, demands accountability, and delivers real results for real people. Your Path to Justice Starts Here.
Los Angeles
11111 Santa Monica
Blvd Suite 1750
Los Angeles, CA 90025
Get Directions
Bay Area
100 Drakes Landing Road
Suite 160
Greenbrae, CA 94904
Get Directions
Washington, D.C.
2101 L St NW 

Suite 800
Washington, DC 20037
Get Directions
The information on this website is for general informational purposes only and does not constitute legal advice. Neither accessing this site nor reviewing its contents creates an attorney-client relationship, so please do not send confidential information until such a relationship is established in writing. This site may be considered attorney advertising. Prior results do not guarantee a similar outcome. Some matters may be handled with or referred to other firms as co-counsel.
Send Us Your Case Details
We’ll respond and let you know the best way to proceed with your case.
crossarrow-up
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram